V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Zoetis Executive Compensation (FY25)

ZTS · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): May 22, 2026
299 figures on this page: 292 cited to the filing that reported them, 7 calculated from figures it prints. See the citations
Kristin Peck, Chief Executive Officer, received $19,046,509 in total compensation for fiscal 2025, and Peck's total moved 10.7% higher from the $17,206,760 reported for fiscal 2024. For fiscal 2025, the company reported a chief executive pay ratio of 236:1, against median employee compensation of $80,592. The say-on-pay proposal drew 85.6% of votes cast for or against in favor at the meeting held May 20, 2026 for fiscal 2025. Companies named in the disclosed peer group include Agilent Technologies, Inc., Baxter International Inc., Becton, Dickinson and Company, Biogen Inc. and Boston Scientific Corporation, among others.
Chief executive, fiscal 2025
◇
Kristin Peck
Latest say-on-pay support
=
May 20, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Kristin Peck: $17,206,760 → $19,046,509 (10.7% higher)
Say-on-pay support: 90.5% → 85.6% (4.9 points lower)
CEO pay ratio: 217:1 → 236:1 (8.8% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Zoetis' chief executive and what were they paid?
Kristin Peck, Chief Executive Officer, received $19,046,509 in total compensation for fiscal 2025. Peck's total moved 10.7% higher from the $17,206,760 reported for fiscal 2024.
What was Zoetis' say-on-pay result?
The say-on-pay proposal drew 85.6% of votes cast for or against in favor at the meeting held May 20, 2026 for fiscal 2025.
Which companies are in Zoetis' peer group?
Companies named in the disclosed peer group include Agilent Technologies, Inc., Baxter International Inc., Becton, Dickinson and Company, Biogen Inc. and Boston Scientific Corporation, among others.
What is Zoetis' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 236:1, against median employee compensation of $80,592.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kristin Peck
Chief Executive Officer
◇—◇◇◇—◇◇
Wetteny Joseph
Executive Vice President (EVP) and Chief Financial Officer
◇—◇◇◇—◇◇
Robert Polzer
Former EVP and President of Research and Development
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kristin Peck
Chief Executive Officer
◇—◇◇◇—◇◇
Wetteny Joseph
Executive Vice President (EVP) and Chief Financial Officer
◇—◇◇◇—◇◇
Jamie Brannan
EVP and Chief Commercial Officer
◇—◇◇◇—◇◇
Robert Polzer
Former EVP and President of Research and Development
◇—◇◇◇—◇◇
Roxanne Lagano
EVP, General Counsel and Corporate Secretary
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kristin Peck
Chief Executive Officer
◇—◇◇◇—◇◇
Wetteny Joseph
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Jamie Brannan
EVP and Chief Commercial Officer
◇—◇◇◇—◇◇
Robert Polzer
Former EVP and President, Research and Development
Departed during or after this year
◇—◇◇◇—◇◇
Roxanne Lagano
EVP, General Counsel and Corporate Secretary
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Jamie BrannanRSU◇——◇——◇
Jamie BrannanOPTION◇——◇—◇◇
Jamie BrannanPSU◇◇◇—◇—◇
Kristin C. PeckRSU◇——◇——◇
Kristin C. PeckOPTION◇——◇—◇◇
Kristin C. PeckPSU◇◇◇—◇—◇
Robert J. PolzerPSU◇◇◇—◇—◇
Robert J. PolzerRSU◇——◇——◇
Robert J. PolzerOPTION◇——◇—◇◇
Roxanne LaganoPSU◇◇◇—◇—◇
Roxanne LaganoOPTION◇——◇—◇◇
Roxanne LaganoRSU◇——◇——◇
Wetteny JosephRSU◇——◇——◇
Wetteny JosephPSU◇◇◇—◇—◇
Wetteny JosephOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Roxanne LaganoOption◇—◇2/6/2034
RSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇2/8/2033
RSU◇◇——
Option◇—◇2/19/2035
PSU◇◇——
Jamie BrannanOption◇—◇2/8/2033
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/19/2035
Option◇—◇2/6/2034
PSU◇◇——
RSU◇◇——
Kristin PeckOption◇—◇2/8/2032
Option◇—◇2/6/2034
RSU◇◇——
Option◇—◇2/19/2035
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/8/2033
PSU◇◇——
Robert PolzerPSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/6/2034
Option◇—◇2/8/2033
Option◇—◇2/19/2035
Wetteny JosephRSU◇◇——
Option◇—◇2/19/2035
RSU◇◇——
Option◇—◇2/6/2034
PSU◇◇——
Option◇—◇2/8/2033
RSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael B. McCallister
Board chair
◇◇————◇
Willie M. Reed
◇◇————◇
Frank A. D'Amelio
◇◇————◇
Gregory Norden
◇◇————◇
Louise M. Parent
◇◇———◇◇
Gavin D.K. Hattersley
◇◇————◇
Vanessa Broadhurst
◇◇———◇◇
Antoinette R. Leatherberry
◇◇———◇◇
Sanjay Khosla
◇◇————◇
Paul M. Bisaro
◇◇————◇
Mark Stetter
◇◇————◇
Robert W. Scully
◇◇————◇
Stephanie Tilenius
◇◇————◇
Kristin C. Peck served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Nominating and governance chair◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Agilent Technologies, Inc. A
  • Baxter International Inc. BAX
  • Becton, Dickinson and Company BDX
  • Biogen Inc. BIIB
  • Boston Scientific Corporation BSX
  • Bristol-Myers Squibb Company BMY
  • Edward Lifesciences Corporation EW
  • Elanco Animal Health Incorporated ELAN
  • Gilead Sciences, Inc GILD
  • IDEXX Laboratories, Inc. IDXX
  • Intuitive Surgical Inc. ISRG
  • IQVIA Holdings Inc. IQV
  • Stryker Corporation SYK
  • Thermo Fisher Scientific Inc. TMO
  • Vertex Pharmaceuticals VRTX
  • Zimmer Biomet Holdings, Inc. ZBH

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 20, 2026=◇◇◇
2024May 21, 2025=◇◇◇
2023May 22, 2024=◇◇◇
2022May 18, 2023=◇◇◇
2021May 19, 2022=◇◇◇
2020May 20, 2021=◇◇◇
2019May 20, 2020=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Zoetis files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Zoetis disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Zoetis sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Zoetis' disclosed peer group is defensible, who names Zoetis back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
299 figures on this page: 292 cited to the filing that reported them, 7 calculated from figures it prints.
292 cited to the filing
7 calculated from the filing

Documents cited

  1. 0001555280-26-000029
  2. 0001555280-26-000015
    CEO Pay Ratio · Compensation of Directors · Outstanding Equity Awards at 2025 Fiscal Year-End · Summary Compensation Table
  3. 0001555280-25-000213
  4. 0001555280-25-000193
    Summary Compensation Table
  5. 0001555280-24-000257
  6. 0001104659-24-045571
    Summary Compensation Table
  7. 0001555280-23-000159
  8. 0001555280-22-000181
  9. 0001555280-21-000231
  10. 0001555280-20-000208
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Zoetis executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/ZTS (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Zoetis and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Zoetis discloses

The companies named in ZTS's own disclosed peer group.

Agilent Technologies, Inc.Baxter International Inc.Becton, Dickinson and CompanyBiogen Inc.Boston Scientific CorporationBristol-Myers Squibb CompanyEdward Lifesciences CorporationElanco Animal Health IncorporatedGilead Sciences, IncIntuitive Surgical Inc.IQVIA Holdings Inc.Stryker CorporationVertex PharmaceuticalsZimmer Biomet Holdings, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy